Cardinal Health, Inc.
CAH Healthcare Medical Distribution
Cardinal Health, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $254.2 billion, up 14.2% from fiscal 2025. In the quarter to June 2026, revenue grew 5.84%, EPS grew 68.3%, free cash flow grew 10.9% and total debt rose 4.21%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow CAH
Cardinal Health, Inc. (CAH) P/B ratio
Cardinal Health, Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 18.5× (November 2019) — the current reading is the lowest in ten years.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 9.3× | 8.89% |
| FY2020 | 8.5× | 278.58% |
| FY2019 | 2.3× | (11.22%) |
| FY2018 | 2.5× | (29.82%) |
| FY2017 | 3.6× | (6.81%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| CAH Cardinal Health, Inc. | n/m |
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| ACH Accendra Health, Inc. compare | n/m |
| MCK McKesson Corporation compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | 0.1× |
| COSM Cosmos Health Inc. compare | 1.0× |
| HSIC Henry Schein, Inc. compare | 2.6× |
| COR Cencora, Inc. compare | 20.3× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on CAH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement